Funding Opportunities

PDBP Funding opportunities (FOAs) support discovery projects designed to promote the identification of promising diagnostic and progression biomarkers for Parkinson's disease.

NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)

Annoucement Type:
Reissue of PAR-18-422
Activity Code:
UG3/UH3
FOA Number:
PAR-21-237
Contact:
Jeremy Brown, MD

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions.  These Phase 3, Phase 4 or Pivotal trials must address questions within the mission and research interests of the NINDS and may include studies of drugs, biologics, and devices, as well as surgical, behavioral or rehabilitation therapies.

*Multiple due dates - see FOA

Treatments for Lewy Body Dementias and Frontotemporal Dementias--Exploratory Clinical Trial (U01 Clinical Trial Required)

Annoucement Type:
New
Application Due Date:
Activity Code:
U01 Research Project - Cooperative Agreements
FOA Number:
RFA-NA-22-056
Contact:
Debra Babcock, PhD, MD

Funding Opportunity Purpose

This Funding Opportunity Announcement invites applications from investigators seeking to conduct exploratory clinical trials designed to test new treatments for patients with Lewy Body Dementia (LBD) or Frontotemporal Dementia (FTD). Applicants may propose to conduct either Phase I or Phase II clinical trials depending on the developmental stage of the potential therapeutic, but all trials must include patients with either LBD or FTD. Proposed therapies may include novel or existing treatments that are potentially beneficial but not currently approved for use in patients with LBD or FTD. Interventions intended to prevent or delay disease progression, as well as therapies to alleviate existing clinical symptoms, are both of interest.